⌕
BioAge Labs · BIOA · Nasdaq
Tenet 74 · Solid
Compare
$5.10−2.30%At closeTenet 74 · Solid
$5.10−0.12 (−2.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

BioAge Labs (BIOA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

12 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue history is too short to read a growth trend, net margin −896.1%.
The four lines that matter · FY23–FY25
Revenue ($M)—
9.0
FY23→FY25CAGR —
Net income ($M)▼13.4%
−80.6
FY23→FY25CAGR —
Free cash flow ($M)▼58.7%
−82.3
FY23→FY25CAGR —
Diluted EPS▲66.2%
−2.24
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)9.0Revenue0.0COGS−74.0R&D−27.8SG&A−92.8Op income12.2Tax & other−80.6Net income

-896¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
108530%sector median net margin ~3%FY23FY25

Net margin -896.1% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY23–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7827, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23YoYCAGR 23→25
Revenue & profitability
Revenue
8.69.00.00.0——
Cost of revenue
—0.00.00.0——
Gross profit
—A—A0.00.0——
Research & development
99.574.059.033.9▲25.3%+47.7%
Selling, general & admin
29.627.819.214.5▲45.2%+38.4%
Total operating expenses
129.1101.878.248.4▲30.2%+45.0%
Operating incomefeeds ROC rank
−120.5−92.8−78.2−48.4▼18.7%—
Other income, net
13.312.47.0−15.5——
Pretax income
−107.3−80.4−71.2−63.9▼12.9%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−107.8−80.6−71.1−63.9▼13.4%—
Per share
Diluted EPSbuyback-sensitive
−2.55−2.24−6.63−38.17▲66.2%—
Diluted shares (mn)
45.9135.9310.731.67▲235.0%+363.5%
Margins
Gross margin
—A—A————
Operating margin
−1401.8%−1031.5%————
Net margin
−1253.6%−896.1%————
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was BioAge Labs' net income?

BioAge Labs reported net income of −$80.6M in fiscal 2025, a net margin of −896.1%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.